Nucleai

Turn tissue into evidence that answers why your ADC works, and which patients benefit. Achieve sharper patient selection, de-risk trials, and inform CDx strategy.

Transform H&E, IHC, multiplex imaging and spatial transcriptomics into actionable tissue intelligence linked to clinical outcomes with Nucleai.

Nucleai expanded its spatial biology platform with deep-learning-enhanced multiplex immunofluorescence (mIF) analysis for drug discovery.

AI Pathology and Spatial Biomarker Solutions for Clinical Trials and Diagnostics Enabling next-gen diagnostics for ADCs, multi-specifics, and IO.

Bio-Techne Corporation and Nucleai presented SECOMBIT clinical trial data at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

To deeply investigate cell–cell interactions, particularly at the frontiers of disease, researchers increasingly are turning to spatial biology.

Antibody-drug conjugates (ADCs) have emerged as one of the busiest and most crowded niches within oncology, given their potential to use an antibody to ferry

Nucleai is creating AI-driven spatial biomarkers, and uses AI to create a map of cells in biopsy tissue samples that can provide all-important information for

Nucleai is a company that uses AI and spatial biology to improve precision medicine and diagnostics by analysing tissue biopsies to predict patient responses

Collaboration demonstrates how AI-powered Tissue Intelligence is transforming biomarker discovery, translational research, and precision oncology development.

TEL AVIV, Israel--(BUSINESS WIRE)--Nucleai, a leader in AI-powered spatial biology analytics, and Sirona Dx, a Technical CRO, specialized in spatial biology

Researchers can explore Nucleai’s Priority Access Program to evaluate its AI platform for multimodal tissue intelligence.

Nucleai develops AI-powered spatial biology tools and precision medicine technologies for cancer drug discovery.

Nucleai’s team combines AI technologists, physicians, and healthcare research professionals.

The page explains how Nucleai integrates multimodal tissue analysis, AI, and clinical outcomes for drug development insights.

Nucleai combines AI-powered multimodal tissue analysis with clinical outcomes to deliver actionable tissue intelligence for biopharma drug development.

Last updated: 12 April, 2026

Last Updated: 12 April, 2026

Last Updated: March 31, 2026

Nucleai secures a spot on *GEN*'s **Top Spatial Biology Companies: Up & Comers 2026** list. The company, which has raised over **$60 million** in total funding, partners with **Gilead Sciences** in an ongoing translational research collaboration announced in August.

Oct 2026NucleaiNews article

Nucleai partners with ADC Therapeutics to apply AI-driven Tissue Intelligence in oncology. The collaboration accelerates biomarker discovery and precision oncology development using large-scale tissue analysis. AI models identify patterns in tumor samples to support translational research and drug development.

Aug 2026NucleaiNews article

Nucleai strengthens its collaboration with the University of Glasgow to expand access to its **multimodal tissue intelligence AI platform**. The partnership facilitates evaluation opportunities through the **Priority Access Program**, targeting researchers and institutions. The platform integrates advanced AI for analyzing tissue samples, supporting medical and scientific applications.

Jul 2026NucleaiNews article

Nucleai and Sirona Dx collaborate to provide an integrated spatial proteomics solution for pharmaceutical drug development. The partnership combines Nucleai’s AI-driven spatial biology analytics with Sirona Dx’s expertise as a technical contract research organization (CRO) in spatial biology. This integration aims to enhance drug discovery and development workflows by leveraging advanced proteomic analysis techniques.

Apr 2026NucleaiNews article